Movers and SHAKERS
NIH Grant Provides Validation for Diabetes Program
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
Ahu Demir, Ph. D., Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Awarded an NIH Grant. Yesterday, Genprex (GNPX) announced that a grant of $2.59 million awarded to the company by the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases. This grant will fund the ongoing preclinical research for proof-of-principle studies in preparation for human gene therapy clinical trials of GPX-002 in type 1 diabetes.
Diverse portfolio with large market potential. Genprex’s lead drug candidate Oncoprex is currently being evaluated in combination with erlotinib for the treatment of non-small cell lung cancer (NSCLC) in Phase 2 clinical study. The company plans to assess Oncoprex in combination with Tagrisso and Keytruda, the trials are expected to commence in the next ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.